Company intelligence / Profile preview

Mirimus

Ownership: Private
Development stage: Preclinical

Overview

Mirimus delivers advanced preclinical CRO services using proprietary gene editing technologies such as RNAi and CRISPR/Cas9 to create custom animal/cell models. The company also develops scalable molecular diagnostic solutions, notably contributing rapid COVID‑19 testing during the pandemic. Its business now spans drug discovery support, RNAi therapeutics R&D, and innovative diagnostics development. No clinical results are reported as it does not develop its own therapeutic pipeline but supports client programs at the preclinical stage.

Therapeutic areas: OtherInfectious Diseases
Modalities: RNA therapy (RNA interference)CRISPR-based therapyInduced pluripotent stem cell derived therapyGenetically engineered animal modelsMolecular diagnostics
Industry: Contract Research Organization

Beyond the preview

Go deeper on Mirimus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mirimus.

Explore the full profile